Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Drug Safety|December 17, 2009
Thorough QT Studies: Questions and QuandariesMarek Malik, Christine E Garnett, Joanne Zhang
Journal of Clinical Pharmacology|January 14, 2011
Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studiesJeffry A Florian, Christoffer W Tornøe, Richard Brundage, et al.
American Journal of Respiratory and Critical Care Medicine|September 16, 2020
Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical TrialsJacqueline V Scott, Christine E Garnett, Manreet K Kanwar, et al.
Journal of Clinical Pharmacology|October 28, 2010
Creation of a knowledge management system for QT analysesChristoffer W Tornøe, Christine E Garnett, Yaning Wang, et al.
Journal of Clinical Pharmacology|February 11, 2010
Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studiesJay W Mason, Jeffry A Florian, Christine E Garnett, et al.
British Journal of Clinical Pharmacology|July 4, 2013
Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalolBorje Darpo, Dilip R Karnad, Fabio Badilini, et al.
Journal of Clinical Pharmacology|December 21, 2007
Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory reviewChristine E Garnett, Nhi Beasley, V Atul Bhattaram, et al.
Nature Reviews. Drug Discovery|November 1, 2011
Clinical pharmacology as a cornerstone of orphan drug developmentEdward D Bashaw, Shiew-Mei Huang, Timothy R Coté, et al.
Therapeutic Innovation & Regulatory Science|September 3, 2022
Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric ExtrapolationThomas R Fleming, Christine E Garnett, Laurie S Conklin, et al.
Pageof 2